High pre-treatment neutrophil-to-lymphocyte ratio as a prognostic marker for worse survival in patients with recurrent/metastatic cervical cancer treated with immune checkpoint inhibitors.

Cervical cancer Checkpoint inhibitors Immunotherapy Neutrophil-to-lymphocyte ratio Prognostic marker

Journal

Gynecologic oncology reports
ISSN: 2352-5789
Titre abrégé: Gynecol Oncol Rep
Pays: Netherlands
ID NLM: 101652231

Informations de publication

Date de publication:
Aug 2022
Historique:
received: 25 05 2022
revised: 30 06 2022
accepted: 03 07 2022
entrez: 20 7 2022
pubmed: 21 7 2022
medline: 21 7 2022
Statut: epublish

Résumé

To evaluate the association between pre-treatment neutrophil-to-lymphocyte ratio (NLR) and survival outcomes among patients with recurrent/metastatic cervical cancer treated with PD-1/PD-L1 inhibitors. A retrospective analysis of patients with recurrent/metastatic cervical cancer treated with PD-1/PD-L1 inhibitors from 2016 to 2021 was conducted. Progression free survival (PFS) and overall survival (OS) outcomes were assessed for patients stratified by NLR (<8 vs ≥ 8) utilizing Kaplan-Meier method. Univariable analysis was performed to compare baseline characteristics between the two groups. A total of 49 patients were included in analysis. A majority of patients had squamous cell histology (57%), were PD-L1 positive (55%), received ≤ 1 prior lines of systemic therapy (57%), and had distant metastatic disease at the time of treatment (69%). The groups were well-balanced with respect to age, race, histology, smoking status, PD-L1 positivity, prior lines of treatment (≤1 vs > 1), prior radiation therapy, ECOG performance status, and disease distribution for patients with a NLR < 8 (n = 35) compared to those with a NLR ≥ 8 (n = 14). A pre-treatment NLR of < 8 was associated with improved survival (p < 0.01), with 57% (95% CI: 41%, 78%) probability of survival at one year compared to 26% (95% CI: 10%, 66%) for those with NLR ≥ 8. No statistically significant differences in probability of PFS at 1 year were seen between NLR < 8 compared to those with NLR ≥ 8 (p = 0.70). Pre-treatment NLR may hold prognostic value for patients with metastatic/recurrent cervical cancer treated with PD-1/PD-L1 inhibitors, with NLR < 8 associated with improved survival.

Identifiants

pubmed: 35855965
doi: 10.1016/j.gore.2022.101040
pii: S2352-5789(22)00120-5
pmc: PMC9287632
doi:

Types de publication

Journal Article

Langues

eng

Pagination

101040

Informations de copyright

Published by Elsevier Inc.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

N Engl J Med. 2021 Nov 11;385(20):1856-1867
pubmed: 34534429
Immunotherapy. 2020 Aug;12(11):785-798
pubmed: 32657234
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Gynecol Oncol. 2021 Nov;163(2):274-280
pubmed: 34452745
J Clin Oncol. 2019 Jun 10;37(17):1470-1478
pubmed: 30943124
Clin Oncol (R Coll Radiol). 2019 Dec;31(12):834-843
pubmed: 31331818
Nat Commun. 2021 Feb 1;12(1):729
pubmed: 33526794
N Engl J Med. 1999 Apr 15;340(15):1144-53
pubmed: 10202165
Lancet Oncol. 2021 May;22(5):609-619
pubmed: 33845034
Lancet Oncol. 2020 Oct;21(10):1353-1365
pubmed: 32919526
Lancet. 2017 Oct 7;390(10103):1654-1663
pubmed: 28756902
Oncologist. 2020 Nov;25(11):e1732-e1742
pubmed: 32785940
J Clin Oncol. 2019 Nov 1;37(31):2825-2834
pubmed: 31487218

Auteurs

Corinne A Calo (CA)

Ohio State University Wexner Medical Center, The Ohio State University, Columbus, OH, United States.
James Cancer Hospital, Division of Gynecologic Oncology, The Ohio State University, Columbus, OH, United States.

David A Barrington (DA)

Ohio State University Wexner Medical Center, The Ohio State University, Columbus, OH, United States.
James Cancer Hospital, Division of Gynecologic Oncology, The Ohio State University, Columbus, OH, United States.

Morgan Brown (M)

Ohio State University Wexner Medical Center, The Ohio State University, Columbus, OH, United States.
Department of Obstetrics and Gynecology, The Ohio State University, Columbus, OH, United States.

Lynette Gonzalez (L)

Ohio State University Wexner Medical Center, The Ohio State University, Columbus, OH, United States.

Jae Baek (J)

Ohio State University Wexner Medical Center, The Ohio State University, Columbus, OH, United States.

Allison Huffman (A)

Ohio State University Wexner Medical Center, The Ohio State University, Columbus, OH, United States.

Jason Benedict (J)

Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University, Columbus, OH, United States.

Floor Backes (F)

Department of Obstetrics and Gynecology, The Ohio State University, Columbus, OH, United States.
James Cancer Hospital, Division of Gynecologic Oncology, The Ohio State University, Columbus, OH, United States.

Laura Chambers (L)

Department of Obstetrics and Gynecology, The Ohio State University, Columbus, OH, United States.
James Cancer Hospital, Division of Gynecologic Oncology, The Ohio State University, Columbus, OH, United States.

David Cohn (D)

Department of Obstetrics and Gynecology, The Ohio State University, Columbus, OH, United States.
James Cancer Hospital, Division of Gynecologic Oncology, The Ohio State University, Columbus, OH, United States.

Larry Copeland (L)

Department of Obstetrics and Gynecology, The Ohio State University, Columbus, OH, United States.
James Cancer Hospital, Division of Gynecologic Oncology, The Ohio State University, Columbus, OH, United States.

Casey Cosgrove (C)

Department of Obstetrics and Gynecology, The Ohio State University, Columbus, OH, United States.
James Cancer Hospital, Division of Gynecologic Oncology, The Ohio State University, Columbus, OH, United States.

Christa Nagel (C)

Department of Obstetrics and Gynecology, The Ohio State University, Columbus, OH, United States.
James Cancer Hospital, Division of Gynecologic Oncology, The Ohio State University, Columbus, OH, United States.

David O'Malley (D)

Department of Obstetrics and Gynecology, The Ohio State University, Columbus, OH, United States.
James Cancer Hospital, Division of Gynecologic Oncology, The Ohio State University, Columbus, OH, United States.

Kristin Bixel (K)

Department of Obstetrics and Gynecology, The Ohio State University, Columbus, OH, United States.
James Cancer Hospital, Division of Gynecologic Oncology, The Ohio State University, Columbus, OH, United States.

Classifications MeSH